Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Financing - ideal

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Jul 13, 2022 9:42am

160 Views

Post# 34820304

RE:RE:RE:RE:RE:Financing - ideal

It makes sense that it is secured by rights to Egrifta. Which means Marathon looked closely at the chances for those revenues to evaporate from generic competition and clearly concluded that is not likely. Also good news.

Wino115 wrote:
Probably Th 1902 trial and commercialization but definitely revenue and cash generation targets. Lenders just want to be paid. Also, it is senior secured, meaning there is something the lender will have ownership over if unpaid --perhaps EGIFTA rights or something like that.

LouisW wrote:
I am curious about what milestones might be. I guess that related to Th1902 or maybe NASH. Will TH disclose the infomation?